Abbisko Cayman Limited is a R&D-driven, clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. Since our inception, we have established a robust in-house R&D engine underpinned by our outstanding discovery team and multi-dimensional discovery platform. Leveraging strong discovery capabilities, we have strategically designed and developed a rich pipeline of 14 programs focused on oncology, including five assets at clinical stage.